// App-Quantinova.ai

e24083 : Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.

Researchers

Presenter

  • Terry L. Ng

Principal Investigators

  • Megan M. Tu

  • Mohammed FK Ibrahim

  • Bassam Mohammed Basulaiman

  • Sharon McGee

  • Amirrtha Srikanthan

  • Ricardo Fernandes

  • Lisa Vandermeer

  • Carol Stober

  • Marta Sienkiewicz

  • Ahwon Jeong

  • Deanna Saunders

  • Arif Ali Awan

  • Brian Hutton

  • Mark J. Clemons

Medical Centers

  • Division of Medical Oncology, The Ottawa Hospital Cancer Centre and Department of Medicine, University of Ottawa, Ottawa, ON, Canada

  • The Ottawa Hospital Research Institute, Ottawa, ON, Canada

  • Division of Clinical Sciences, Medical Oncology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada

  • King Abdulaziz Medical City, Riyadh, Saudi Arabia

  • Division of Medical Oncology, Department of Oncology, London Regional Cancer Program, London Health Sciences Centre and University of Western Ontario,, London, ON, Canada

  • School of Epidemiology and Public Health, Ottawa University, Ottawa, Ontario, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Observational

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved